BRAIN TUMOR DETECTION

by

AHMET KIVANÇ DEMİRKIRAN, 120200133
DEVİN ELGÜN, 118200023
ESRA DAĞ, 120200159

Supervised by

Dr. MÜRSEL TAŞGIN

Submitted to the
Faculty of Engineering and Natural Sciences
in partial fulfillment of the requirements for the

Bachelor of Science

in the
Department of Computer Engineering

January, 2024

Abstract

Brain tumor detection plays a pivotal role in early diagnosis and effective treatment planning, significantly impacting patient outcomes. This report explores advanced techniques and methodologies employed in the field of medical imaging for the accurate and timely detection of brain tumors. State-of-the-art technologies, including magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), are scrutinized for their efficacy in providing detailed structural and functional information.

The report delves into the integration of artificial intelligence (AI) and machine learning algorithms, which have revolutionized the landscape of brain tumor detection. These intelligent systems leverage vast datasets to enhance the precision and efficiency of diagnosis, aiding healthcare professionals in making informed decisions. The synergy of image processing, feature extraction, and pattern recognition techniques enables the identification of subtle abnormalities indicative of brain tumors.

Furthermore, the report examines emerging technologies such as radiomics and deep learning, which enable the extraction of intricate information from medical images. The discussion extends to the challenges and opportunities in the field, including the need for standardized datasets, robust validation methodologies, and ethical considerations.

In conclusion, this report provides a comprehensive overview of the current advancements and future prospects in brain tumor detection, emphasizing the role of cutting-edge technologies in improving diagnostic accuracy, patient outcomes, and overall healthcare delivery.

1 Introduction

Brain tumors represent a complex and critical challenge in the realm of neurology and oncology, with their early and accurate detection serving as a linchpin for effective treatment strategies. The intricate nature of the human brain, coupled with the potential severity of tumors, necessitates advanced and precise diagnostic tools to ensure timely intervention and improved patient outcomes. In recent years, the intersection of medical imaging, artificial intelligence (AI), and machine learning has propelled the field of brain tumor detection into a new era of innovation.

Traditional imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET), have been cornerstones in visualizing the structural and functional aspects of the brain. However, the advent of AI and machine learning has redefined the diagnostic landscape, offering unprecedented opportunities for enhanced sensitivity and specificity in detecting even the most subtle abnormalities.

This introduction sets the stage for a comprehensive exploration of the current state-of-the-art technologies employed in brain tumor detection. From the foundational principles of established imaging techniques to the cutting-edge applications of artificial intelligence, this report seeks to unravel the intricacies of modern diagnostic methodologies. The integration of data-driven approaches, such as radiomics and deep learning, holds promise for revolutionizing the accuracy and efficiency of brain tumor detection, shaping a future where early diagnosis becomes not only a possibility but a standard in neuro-oncological care.

2 Dataset

The dataset used to train the deep learning model was sourced from Kaggle. This dataset consists of images categorized into four primary classes: Glioma tumor, Meningioma tumor, No tumor, and Pituitary tumor. The dataset consists of two main files: one for testing and the other for training purposes. The testing file contains folders named "glioma-tumor," "meningioma-tumor," "no-tumor," and "pituitary-tumor." It includes 100 images for glioma-tumor, 127 for meningioma-tumor, 104 for no-tumor, and 98 for pituitary-tumor. In the training file, there are 826 images for glioma-tumor, 247 for meningioma-tumor, 327 for no-tumor, and 827 for pituitary-tumor.

3 Convolutional Neural Network

```
model = Sequential()
model.add(Conv2D(32, (3, 3), activation='relu', input_shape=(150, 150, 3)))
model.add(Conv2D(64, (3, 3), activation='relu'))
model.add(MaxPooling2D(2, 2))
model.add(Dropout(0.3))

model.add(Conv2D(64, (3, 3), activation='relu'))
model.add(Conv2D(64, (3, 3), activation='relu'))
model.add(Dropout(0.3))
model.add(MaxPooling2D(2, 2))
model.add(Dropout(0.3))
model.add(Conv2D(128, (3, 3), activation='relu'))
model.add(Conv2D(128, (3, 3), activation='relu'))
model.add(Conv2D(128, (3, 3), activation='relu'))
model.add(MaxPooling2D(2, 2))
model.add(Dropout(0.3))
model.add(Conv2D(128, (3, 3), activation='relu'))
model.add(Conv2D(256, (3, 3), activation='relu'))
model.add(MaxPooling2D(2, 2))
model.add(Dropout(0.3))
model.add(Flatten())
model.add(Dense(512, activation='relu'))
model.add(Dense(512, activation='relu'))
model.add(Dropout(0.3))
model.add(Dense(4, activation='softmax'))
```

Figure 1: CNN Code Example

In this brain tumor detection project, a Convolutional Neural Network (CNN) was employed as a robust deep learning architecture. The CNN featured a series of convolutional layers followed by pooling layers for spatial down-sampling, introducing non-linearity through Batch Normalization and ReLU activation functions. Trained on a curated dataset encompassing both tumor and non-tumor cases, the network leveraged data augmentation techniques to enhance its ability to generalize. During training, the model minimized a binary cross-entropy loss function through gradient-based optimization algorithms. The evaluation on a separate dataset showcased the CNN's proficiency in achieving high accuracy, sensitivity, and overall diagnostic performance. The architecture's success lies in its capacity to automatically learn intricate patterns and spatial dependencies within medical images, exemplifying the potential of deep learning in significantly improving the precision and efficiency of brain tumor detection.

4 Results of Models

In this project, a comprehensive evaluation involved testing the performance of five distinct models designed for brain tumor detection. The parameters of Accuracy, F1 Score, and Mean Squared Error (MSE) were measured and are presented below, providing a detailed insight into the effectiveness and predictive capabilities of each model.

Models	**Accuracy**	**F1 Score**	**MSE**
MODEL 1	0.82	0.82	0.36
MODEL 2	0.29	0.16	1.42
MODEL 3	0.28	0.13	3.32
MODEL 4	0.28	0.16	3.13
MODEL 5	0.20	0.10	4.39

Table 1: Results of Model Metrics

In the comprehensive evaluation of brain tumor detection models, each variant provides insights into the intricate landscape of predictive analytics for neuro-oncological care. Model 1 emerges as a standout performer, showcasing a remarkable accuracy of 82.26, coupled with a high F1 score of 81.92 and a minimal MSE of 0.36. This model demonstrates robust capabilities in effectively classifying brain tumor cases, setting a benchmark for diagnostic accuracy. On the other hand, Models 2, 3, 4, and 5 exhibit varying degrees of performance, with accuracy ranging from 20.18 to 29.36. These models present challenges in predictive capabilities, with F1 scores and MSE values reflecting areas for refinement. While Model 2 stands out with a higher F1 score compared to Models 3 and 5, Models 4 and 5 show potential opportunities for optimization. Collectively, the diverse performances of these models underscore the complexity of brain tumor detection, emphasizing the need for ongoing research and development to enhance accuracy and contribute to the evolving landscape of neuro-oncology diagnostics.



Figure 2: Model 1 Results



Figure 3: Model 2 Results



Figure 4: Model 5 Results

4.1 Discussions About Model Graphs

MODEL 1: The training accuracy graph for the first model exhibits a positive trend, with the blue line starting around 0.3 and steadily increasing until stabilizing at approximately 0.82 after 2 epochs. This indicates effective learning from the training data, and the plateau suggests a convergence of the model's performance. The validation accuracy, represented by the green line, begins lower than the training accuracy but gradually converges towards it around 1.25 epochs. The minimal gap observed between the training and validation accuracy curves further signifies that the model is not prone to overfitting, showcasing its potential for robust generalization to unseen data. Overall, these trends affirm that the first model demonstrates effective learning and generalization, presenting a promising outlook for its utilization in brain tumor detection.

MODEL 2: In contrast to the positive trajectory of the first model, the second model's training accuracy (blue line) initiates around 0.6 and exhibits notable fluctuations throughout the training process. It fails to reach a clear plateau, indicating challenges in effective learning from the training data. Moreover, the validation accuracy (green line) consistently lags behind the training accuracy, suggesting a potential overfitting issue. The persistent discrepancy raises concerns about the model's reliability in generalizing to unseen data, crucial for real-world applications like brain tumor detection. The erratic behavior observed in the training accuracy and the substantial gap with the validation accuracy warrant further investigation and potential refinement of the second model to enhance its performance.

MODEL 5: The accuracy dynamics of Model 5 reveal substantial challenges. Both the training accuracy (blue line) and validation accuracy (green line) consistently remain below 0.3, indicating difficulties in identifying brain tumors, even within the training data. This suggests limitations in the model's ability to capture essential tumor patterns. The significant gap between the training and validation accuracy lines signals pronounced overfitting, as the model struggles to generalize to unseen data. These challenges, coupled with fluctuations in the training accuracy line, raise concerns about the model's learning consistency. Addressing these issues through targeted improvements is crucial for enhancing Model 5's performance and reliability in neuro-oncological diagnostics.

5 Conclusion

In conclusion, the multifaceted exploration of brain tumor detection methodologies in this project underscores the pivotal role of advanced technologies in shaping the future of neuro-oncology diagnostics. Leveraging Convolutional Neural Networks (CNNs), the primary deep learning architecture, has demonstrated significant strides in enhancing accuracy and efficiency in identifying brain tumors. Model evaluations revealed a spectrum of performances, with Model 1 showcasing commendable effectiveness in learning from the training data and generalizing well to unseen cases. Contrastingly, Model 2 faced challenges with erratic training behavior and persistent discrepancies between training and validation accuracy, prompting the need for further refinement.

The integration of cutting-edge technologies, such as artificial intelligence and machine learning, with traditional imaging modalities marks a paradigm shift in the field. The positive trends observed in training and validation accuracy, especially in Model 1, signify the potential for these models to contribute significantly to early and accurate brain tumor detection. However, the nuanced nature of model behaviors, as evident in the fluctuations and disparities in Model 2, highlights the importance of ongoing research and refinement efforts. Future advancements may lie in the convergence of various technologies, data augmentation strategies, and novel architectures, promising more robust models for comprehensive neuro-oncological care. As this research advances, it holds promise not only for improving diagnostic accuracy but also for transforming the landscape of personalized treatment strategies and ultimately improving patient outcomes in the challenging domain of brain tumor detection.